Jay David Caplan Sells 64,197 Shares of Fractyl Health, Inc. (NASDAQ:GUTS) Stock

Fractyl Health, Inc. (NASDAQ:GUTS) insider Jay David Caplan sold 64,197 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $2.47, for a total transaction of $158,566.59. Following the transaction, the insider now owns 153,544 shares in the company, valued at approximately $379,253.68. The trade was a 29.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Jay David Caplan also recently made the following trade(s):

• On Thursday, September 12th, Jay David Caplan sold 65,000 shares of Fractyl Health stock. The stock was sold at an average price of $2.90, for a total transaction of $188,500.00.

Fractyl Health Stock Down 11.8 %

NASDAQ:GUTS opened at $2.09 on Friday. Fractyl Health, Inc. has a one year low of $1.74 and a one year high of $14.50. The firm’s fifty day moving average price is $2.61 and its two-hundred day moving average price is $4.04. The company has a current ratio of 5.58, a quick ratio of 7.46 and a debt-to-equity ratio of 0.60.

Fractyl Health (NASDAQ:GUTS) last announced its earnings results on Tuesday, November 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.02. The business had revenue of $0.01 million during the quarter. On average, analysts anticipate that Fractyl Health, Inc. will post -1.61 EPS for the current year.

Institutional Investors Weigh In On Fractyl Health

Institutional investors and hedge funds have recently bought and sold shares of the company. Rhumbline Advisers acquired a new position in shares of Fractyl Health in the second quarter valued at approximately $32,000. SG Americas Securities LLC acquired a new position in shares of Fractyl Health in the third quarter valued at approximately $33,000. Renaissance Technologies LLC acquired a new position in shares of Fractyl Health in the second quarter valued at approximately $61,000. Beta Wealth Group Inc. acquired a new position in shares of Fractyl Health in the third quarter valued at approximately $44,000. Finally, BNP Paribas Financial Markets increased its stake in shares of Fractyl Health by 54.1% in the third quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock valued at $53,000 after buying an additional 7,397 shares during the period.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.